Cipla inks partnership with China’s Qilu Pharma for cancer biosimilar
The partnership reflects Cipla’s confidence in the long-term potential of biosimilars and supports its strategy to build a strong oncology-focused portfolio.
We haven't written up this one. The Hindu - Sci-Tech has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.